Advances in the genetics of schizophrenia

Toward a network and pathway view for drug discovery

David A. Collier, Brian J. Eastwood, Karim Malki, Younes Mokrab

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The spectacular advance in our understanding of the genetic basis of schizophrenia through genome-wide association studies has the potential to identify new leads for drug treatment through improved understanding of disease pathophysiology. However, using these genetic associations successfully in drug development and patient stratification requires further target validation, particularly in understanding which gene(s) is causal in the disease, how the risk variants alter gene function and regulation, and how they fit into disease pathways and networks. If researchers consider the disease network as the target, they need to understand which genes should be targeted and in which modality, in order to modulate pathophysiology and obtain a beneficial effect for the patient. In the present article, we review recent genetic findings in schizophrenia and discuss how these might be validated with biology and integrated with epigenetic and transcriptome data to identify targets that lie within disease networks and pathways. This new understanding of disease biology will also facilitate the development of assays that recapitulate specific aspects of the disease using model organisms and cells. These assays can then be used in screening approaches, which manipulate disease networks or pathological processes to generate and test therapeutic strategies.

Original languageEnglish
Pages (from-to)61-75
Number of pages15
JournalAnnals of the New York Academy of Sciences
Volume1366
Issue number1
DOIs
Publication statusPublished - 1 Feb 2016

Fingerprint

Drug Discovery
Schizophrenia
Genes
Assays
Drug therapy
Genetics
Pathway
Genetics of Schizophrenia
Drugs
Genome-Wide Association Study
Pathologic Processes
Transcriptome
Epigenomics
Pharmaceutical Preparations
Screening
Research Personnel
Association reactions
Therapeutics
Gene

Keywords

  • Drug discovery
  • Genome-wide association
  • Pharmacogenetics
  • Psychosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Advances in the genetics of schizophrenia : Toward a network and pathway view for drug discovery. / Collier, David A.; Eastwood, Brian J.; Malki, Karim; Mokrab, Younes.

In: Annals of the New York Academy of Sciences, Vol. 1366, No. 1, 01.02.2016, p. 61-75.

Research output: Contribution to journalArticle

@article{42cec4cec84c4402bd168d9fc9a4b091,
title = "Advances in the genetics of schizophrenia: Toward a network and pathway view for drug discovery",
abstract = "The spectacular advance in our understanding of the genetic basis of schizophrenia through genome-wide association studies has the potential to identify new leads for drug treatment through improved understanding of disease pathophysiology. However, using these genetic associations successfully in drug development and patient stratification requires further target validation, particularly in understanding which gene(s) is causal in the disease, how the risk variants alter gene function and regulation, and how they fit into disease pathways and networks. If researchers consider the disease network as the target, they need to understand which genes should be targeted and in which modality, in order to modulate pathophysiology and obtain a beneficial effect for the patient. In the present article, we review recent genetic findings in schizophrenia and discuss how these might be validated with biology and integrated with epigenetic and transcriptome data to identify targets that lie within disease networks and pathways. This new understanding of disease biology will also facilitate the development of assays that recapitulate specific aspects of the disease using model organisms and cells. These assays can then be used in screening approaches, which manipulate disease networks or pathological processes to generate and test therapeutic strategies.",
keywords = "Drug discovery, Genome-wide association, Pharmacogenetics, Psychosis",
author = "Collier, {David A.} and Eastwood, {Brian J.} and Karim Malki and Younes Mokrab",
year = "2016",
month = "2",
day = "1",
doi = "10.1111/nyas.13066",
language = "English",
volume = "1366",
pages = "61--75",
journal = "Annals of The Lyceum of Natural History of New York",
issn = "0890-6564",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Advances in the genetics of schizophrenia

T2 - Toward a network and pathway view for drug discovery

AU - Collier, David A.

AU - Eastwood, Brian J.

AU - Malki, Karim

AU - Mokrab, Younes

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The spectacular advance in our understanding of the genetic basis of schizophrenia through genome-wide association studies has the potential to identify new leads for drug treatment through improved understanding of disease pathophysiology. However, using these genetic associations successfully in drug development and patient stratification requires further target validation, particularly in understanding which gene(s) is causal in the disease, how the risk variants alter gene function and regulation, and how they fit into disease pathways and networks. If researchers consider the disease network as the target, they need to understand which genes should be targeted and in which modality, in order to modulate pathophysiology and obtain a beneficial effect for the patient. In the present article, we review recent genetic findings in schizophrenia and discuss how these might be validated with biology and integrated with epigenetic and transcriptome data to identify targets that lie within disease networks and pathways. This new understanding of disease biology will also facilitate the development of assays that recapitulate specific aspects of the disease using model organisms and cells. These assays can then be used in screening approaches, which manipulate disease networks or pathological processes to generate and test therapeutic strategies.

AB - The spectacular advance in our understanding of the genetic basis of schizophrenia through genome-wide association studies has the potential to identify new leads for drug treatment through improved understanding of disease pathophysiology. However, using these genetic associations successfully in drug development and patient stratification requires further target validation, particularly in understanding which gene(s) is causal in the disease, how the risk variants alter gene function and regulation, and how they fit into disease pathways and networks. If researchers consider the disease network as the target, they need to understand which genes should be targeted and in which modality, in order to modulate pathophysiology and obtain a beneficial effect for the patient. In the present article, we review recent genetic findings in schizophrenia and discuss how these might be validated with biology and integrated with epigenetic and transcriptome data to identify targets that lie within disease networks and pathways. This new understanding of disease biology will also facilitate the development of assays that recapitulate specific aspects of the disease using model organisms and cells. These assays can then be used in screening approaches, which manipulate disease networks or pathological processes to generate and test therapeutic strategies.

KW - Drug discovery

KW - Genome-wide association

KW - Pharmacogenetics

KW - Psychosis

UR - http://www.scopus.com/inward/record.url?scp=84969240170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969240170&partnerID=8YFLogxK

U2 - 10.1111/nyas.13066

DO - 10.1111/nyas.13066

M3 - Article

VL - 1366

SP - 61

EP - 75

JO - Annals of The Lyceum of Natural History of New York

JF - Annals of The Lyceum of Natural History of New York

SN - 0890-6564

IS - 1

ER -